Accelerated Biosciences has formed a partnership with Spanios tumor therapy research firm to develop oncology therapeutics from its human trophoblast stem cell (hTSC) platform.
The partnership aims to bring together Spanios' COMPASS platforms and patient-derived tumor models with AcceleratedBio's hTSC platform to improve therapy designs for solid tumor cancers. Accelerated Biosciences will provide ethically sourced pluripotent stem cells with potential use in wide-ranging medical and biotech applications. Spanios, with its expertise in tumoroid research and ability to simulate preclinical therapeutic performance rapidly, will generate clinically relevant data for these stem cells. This collaboration aims to enhance cell-based therapies, specifically for challenging cancers such as Ovarian and Colorectal.
Spanios is a precision oncology company using its proprietary patient-derived 3D tumoroid (PDT) platform to study the biological complexity of solid tumors in order to develop treatments. The platform creates a replica of host tumor environments with customizable testing conditions to study drug responses and efficacy.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.